OP06: HLA-DQA1*05:01 is associated with loss of response to infliximab, and HLA DQA1*05:05 with loss of response to adalimumab in the Oxford OASIS studyECCO'25 Berlin 2025
OP07: Psychosocial factors are associated with risk of flare in IBD; results from the PREdiCCt studyECCO'25 Berlin 2025
OP08: Histology-derived cell-cell interaction networks, linked to transcriptome profiling, define path to resolution in UCECCO'25 Berlin 2025
OP09: Dose intensification of vedolizumab is not effective in inducing endoscopic response in Crohn’s disease patients with endoscopic primary non-responseECCO'25 Berlin 2025
OP10: Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO studyECCO'25 Berlin 2025
OP12: Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn’s diseaseECCO'25 Berlin 2025
OP13: Higher neoplasia detection rate and lower number of targeted biopsies associated with virtual chromoendoscopy in IBD surveillance: a real-world, multicentre UK studyECCO'25 Berlin 2025
OP14: The United European Gastroenterology green paper—climate change and gastroenterologyECCO'25 Berlin 2025
OP17: Defining radiological healing in perianal fistulising Crohn’s Disease: a global modified Delphi consensusECCO'25 Berlin 2025
OP18: Multi-analytical Approaches Reveal Robust Gut Microbial Biomarkers for Inflammatory Bowel Disease Diagnosis: A Large-scale Cohort StudyECCO'25 Berlin 2025
OP20: Expanding the genetic spectrum of inflammatory bowel disease through large-scale exome sequencingECCO'25 Berlin 2025
OP21: MIF-CD74 signaling promotes intestinal LTi-like ILC3s activation and gut fibrosis via upregulating pSTAT3ECCO'25 Berlin 2025
OP22: NR1D1 Deficiency Induces CD47 Upregulation Impairing Macrophage Efferocytosis and Exacerbating Intestinal Inflammation in Ulcerative ColitisECCO'25 Berlin 2025